Impact BioMedical Inc. Announces the Closing of its Initial Public Offering
17 Septembre 2024 - 5:29PM
Impact BioMedical Inc. (NYSE American: IBO), a company
discovering and developing new offerings in human healthcare and
wellness, today announced the closing of its previously announced
initial public offering of 1,500,000 shares of its common stock at
a public offering price of $3.00 per share. The shares began
trading on the NYSE American Market on September 16, 2024, under
the ticker symbol “IBO”.
In addition, Impact has granted the underwriters a 45-day option
to purchase up to an additional 225,000 shares of its common stock
at the public offering price, less underwriting discounts and
commissions. All of the shares of common stock are being offered by
Impact BioMedical. Revere Securities, LLC is the sole book-running
manager for the offering.
We have issued to Revere Securities warrants to purchase up to
75,000 shares of our common stock (or 86,250 shares assuming the
over-allotment option is exercised in full), representing five
percent (5%) of the number of shares of our common stock sold in
each offering. The warrants are exercisable at $3.75 per share,
equal to 125% of the initial public offering price per share at any
time and from time to time, in whole or in part, commencing nine
months after the commencement of sales in the offering to the third
anniversary thereof.
A registration statement on Form S-1 relating to the offering
was filed with the Securities and Exchange Commission (the "SEC")
(File Number: 333-275062) and was declared effective by the SEC
on September 13, 2024. The offering was made only by means of
a prospectus, forming a part of the registration statement. Copies
of the final prospectus relating to the Offering may be obtained
via the SEC's website at www.sec.gov.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy these securities, nor shall there
be any sale of these securities in any state or jurisdiction in
which such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or jurisdiction.
About Impact BioMedical Inc.:Impact BioMedical
Inc. (“IBO”) discovers, confirms, and patents unique science and
technologies resulting in new offerings in human healthcare and
wellness. Once available, IBO works closely with licensing,
co-development, joint ventures, and other relationships to bring
these offerings to market. For more information, visit Impact
Biomedical, Inc. | Reverse Engineering Nature
(impactbiomedinc.com).
Safe Harbor Disclosure:This press release
contains forward-looking statements within the meaning of Section
27A of the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934. These statements are subject to risks and
uncertainties that may cause actual results or events to differ
materially from those projected. Readers are cautioned not to place
undue reliance on forward-looking statements, which speak only as
of the date.
Media Contact:Emily Martin
Email: emartin@impactbiomedinc.com
Investor Relations:info@impactbiomedinc.com
Impact Biomedical (AMEX:IBO)
Graphique Historique de l'Action
De Nov 2024 à Déc 2024
Impact Biomedical (AMEX:IBO)
Graphique Historique de l'Action
De Déc 2023 à Déc 2024